Leap Therapeutics, Inc.'s DKN-01 trial results show mixed outcomes in cancer treatment, prompting potential future funding needs. Click for my LPTX stock update.

Leap Therapeutics (LPTX) lost 63% after announcing it will not run a Phase 3 trial for its lead asset sirexatamab in gastric cancer. Read more here.

Despite its significant role in personalizing care, many oncology care providers from a community setting reported not testing patients with gastric and gastroesophageal junction (GEJ) cancers for ...

Thoracoabdominal esophagectomy was performed for esophageal tumors and for esophagogastric junction tumors extending into the esophagus. For esophagogastric junction tumors, a thoracoabdominal ...

Leap Therapeutics (LPTX) announced positive initial data from Part B of the DeFianCe study evaluating sirexatamab in combination with ...